"Following a recommendation by management, our board of
directors approved a proposal to hire the Emmes Group to help
develop and evaluate various strategic opportunities," said Judy
Robinett, president and CEO of Medical Discoveries Inc. "We are
considering a wide range of options, including partnerships,
mergers, acquisitions, and divesting certain drug development
programs. There is, however, no guarantee that Medical Discoveries
will pursue any of these alternatives. Medical Discoveries does not
plan to make future comments on this process unless there are
material developments."

The Emmes Group is a strategy consulting firm supporting clients
engaged in the technology and healthcare industries. With offices
in Boston and San Francisco, the Emmes Group works in partnership
with its clients to build lasting economic value. The firm's
managing partners' expertise spans a number of key areas,
including: Strategy Consulting, Mergers & Acquisitions,
Strategic Marketing, Technology Licensing, Corporate Finance,
Market Research & Modeling, and Investor Due Diligence. The
firm's website is located at: http://www.emmesgroup.com

About Medical Discoveries

Medical Discoveries, Inc. develops cures for major diseases
though its novel oxidative therapy program ("MDI-P"), and
in-licensing promising technologies that address some of today's
most serious illnesses. The Company was founded on MDI-P, a novel
oxidative therapy that is a stable solution rich in highly reactive
hydrogen, chlorine and oxygen chain species. MDI-P has demonstrated
potential to work directly on pathogens, or as an enhancer to the
immune system. The Company's European partner, Eucodis, a
biotechnology company located in Austria, is developing Formestane
cream, a topical treatment for breast cancer. http://www.medicaldiscoveries.com

Forward Looking Statements

This news release contains forward-looking statements that
involve significant risks and uncertainties, including those
discussed below and others that can be found in the Company's Form
10 KSB for the year ended December 31, 2005, and in the Company's
periodic reports filed with the Securities and Exchange Commission.
Medical Discoveries is providing this information as of the date of
this news release, and does not undertake any obligation to update
any forward-looking statements contained in this document as a
result of new information, future events or otherwise.